532 related articles for article (PubMed ID: 19427988)
1. Ranibizumab for refractory uveitis-related macular edema.
Acharya NR; Hong KC; Lee SM
Am J Ophthalmol; 2009 Aug; 148(2):303-309.e2. PubMed ID: 19427988
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
4. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for treatment of uveitic macular edema.
Cordero Coma M; Sobrin L; Onal S; Christen W; Foster CS
Ophthalmology; 2007 Aug; 114(8):1574-1579.e1. PubMed ID: 17363060
[TBL] [Abstract][Full Text] [Related]
6. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema.
Taylor SR; Habot-Wilner Z; Pacheco P; Lightman SL
Ophthalmology; 2009 Apr; 116(4):797-801. PubMed ID: 19344827
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
[TBL] [Abstract][Full Text] [Related]
8. Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema.
Acharya NR; Sittivarakul W; Qian Y; Hong KC; Lee SM
Retina; 2011 Oct; 31(9):1871-6. PubMed ID: 21716165
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study.
Mackensen F; Heinz C; Becker MD; Heiligenhaus A
Retina; 2008 Jan; 28(1):41-5. PubMed ID: 18185136
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema.
Morrison VL; Kozak I; LaBree LD; Azen SP; Kayicioglu OO; Freeman WR
Ophthalmology; 2007 Feb; 114(2):334-9. PubMed ID: 17270681
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal adalimumab for refractory uveitis-related macular edema.
Androudi S; Tsironi E; Kalogeropoulos C; Theodoridou A; Brazitikos P
Ophthalmology; 2010 Aug; 117(8):1612-6. PubMed ID: 20378179
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY;
Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
[TBL] [Abstract][Full Text] [Related]
17. Outcome of intravitreal triamcinolone in uveitis.
Kok H; Lau C; Maycock N; McCluskey P; Lightman S
Ophthalmology; 2005 Nov; 112(11):1916.e1-7. PubMed ID: 16171868
[TBL] [Abstract][Full Text] [Related]
18. Adverse events after intravitreal infliximab (Remicade).
Giganti M; Beer PM; Lemanski N; Hartman C; Schartman J; Falk N
Retina; 2010 Jan; 30(1):71-80. PubMed ID: 19996827
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.
Chun DW; Heier JS; Topping TM; Duker JS; Bankert JM
Ophthalmology; 2006 Oct; 113(10):1706-12. PubMed ID: 17011952
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
